CA-INSEEGO
31.3.2021 15:07:07 CEST | Business Wire | Press release
Inseego Corp. (Nasdaq: INSG), a leader in 5G and IoT device-to-cloud solutions, today announced that its Wavemaker PRO 5G indoor router FX2000e has been certified for use in several markets globally. This plug-and-play fixed wireless solution provides 5G/LTE broadband with ethernet and Wi-Fi 6 connectivity for up to 32 devices, making it ideal for small businesses and distributed employees who need fast, reliable and highly secure internet access.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210331005341/en/
With gigabit-class 5G speeds, the FX2000e delivers fast, reliable connectivity almost anywhere, from restaurant and retail locations to branch offices and home offices. The Inseego Mobile app provides an intuitive UI and makes it easy for end users to self-install their devices. Using Inseego Connect cloud softwarei , IT managers can remotely configure and manage all devices in a highly scalable deployment.
“5G solutions provide a great choice for broadband access for businesses and consumers in their distributed offices and homes,” said Inseego President of IoT & Mobile Solutions Ashish Sharma. “Our FX2000e is a compact solution that supports many different use cases for broadband connectivity: Small businesses can get fast internet access anywhere. Enterprises can easily deploy a secure WAN solution for their branch offices and remote employees. And SD WAN providers can now rely on a 5G WAN connection as a primary broadband connection for distributed locations.”
Flexible 5G connectivity
The FX2000e is certified to operate in a broad range of global 5G and 4G frequency bands. Designed as a powerful and cost-effective solution for last-mile internet access, it can bring high-speed broadband connectivity to users on leading 4G and 5G networks in global markets.
With its small form factor, the FX2000e can be deployed as the primary broadband solution for distributed retail locations, as an add-on WAN interface for SD WAN deployments, as an internet solution for small occupancy homes, or as a cable modem replacement for larger homes with mesh Wi-Fi systems and other connectivity needs.
Fast, flexible, reliable and secure
- Gigabit-class 5G and LTE speeds
- Robust connectivity with ethernet and Wi-Fi 6 for up to 32 devices
- Dual-SIM functionality for up to two carrier SIMs, with auto-switching between cellular networks and ethernet WAN
- Enterprise-grade security with OpenVPN, access control, end-to-end device security, threat identification, monitoring, threat alerts and other protectionsii
- Inseego Connect™ Advanced cloud management
- Continuous software updates, security and support
Availability
The Inseego Wavemaker™ PRO 5G indoor CPE FX2000e has received regulatory certifications for use in several regions worldwide, including FCC Band 48 support for CBRS networks, and is now available through major distributors in North America and Europe. Please contact Inseego to learn more.
A broad portfolio of 5G FWA solutions for consumers and enterprise customers
In addition to the FX2000e, the Inseego Wavemaker PRO portfolio includes the 5G indoor CPE FG2000e, which is currently commercially available in several markets. The portfolio also includes two 5G outdoor CPEs and a 5G industrial gateway. Please contact Inseego to learn more about these solutions.
Trusted and secure
Designed and developed in the U.S., Inseego solutions are trusted by leading mobile operators, government agencies and enterprise customers worldwide. To learn more about Inseego 5G products and solutions go to inseego.com . For press and analyst inquires, please email press@inseego.com .
About Inseego Corp.
Inseego Corp. (Nasdaq: INSG) is an industry leader in smart device-to-cloud solutions that extend the 5G network edge, enabling broader 5G coverage, multi-gigabit data speeds, low latency and strong security to deliver highly reliable internet access. Our innovative mobile broadband, fixed wireless access (FWA) solutions, and software platform incorporate the most advanced technologies (including 5G, 4G LTE, Wi-Fi 6 and others) into a wide range of products that provide robust connectivity indoors, outdoors and in the harshest industrial environments. Designed and developed in the USA, Inseego products and SaaS solutions build on the company’s patented technologies to provide the highest quality wireless connectivity for service providers, enterprises, and government entities worldwide. www.inseego.com #Putting5GtoWork
©2021 Inseego Corp. All rights reserved. The Inseego name and logo are registered trademarks, and the Wavemaker and Inseego Manage names are trademarks of Inseego Corp.
________________
i
Base version (free) enables a user to manage a single FX2000e device settings easily using the Inseego Mobile app or Web UI. For management of multiple devices, an Inseego Connect Standard or Inseego Connect Advanced subscription is required, providing advanced device management, provisioning, monitoring, and diagnostics for multiple devices from a single dashboard.
ii Contact Inseego to learn more about available advanced security solutions.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210331005341/en/
Link:
Social Media:
https://www.facebook.com/Inseego/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom